

David M Epstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3484644/publications.pdf>

Version: 2024-02-01

76
papers

5,819
citations

186209

28
h-index

74108

75
g-index

87
all docs

87
docs citations

87
times ranked

5798
citing authors

#	ARTICLE	IF	CITATIONS
1	Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR) Tj ETQq1 1 0.784314 rgBT /Overlock	6.3	1,386
2	Endovascular versus Open Repair of Abdominal Aortic Aneurysm. New England Journal of Medicine, 2010, 362, 1863-1871.	13.9	1,242
3	A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials. Pharmacoeconomics, 2014, 32, 1157-1170.	1.7	417
4	Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. British Journal of Surgery, 2017, 104, 166-178.	0.1	304
5	Endovascular Repair of Aortic Aneurysm in Patients Physically Ineligible for Open Repair. New England Journal of Medicine, 2010, 362, 1872-1880.	13.9	293
6	A Randomized Trial of Early Endovenous Ablation in Venous Ulceration. New England Journal of Medicine, 2018, 378, 2105-2114.	13.9	244
7	The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of EVAR versus standard therapy.. Health Technology Assessment, 2012, 16, 1-218.	1.3	193
8	The UK Endovascular Aneurysm Repair (EVAR) Trials: Design, Methodology and Progress. European Journal of Vascular and Endovascular Surgery, 2004, 27, 372-381.	0.8	125
9	Stapled haemorrhoidopexy for the treatment of haemorrhoids: a systematic review. Colorectal Disease, 2009, 11, 233-243.	0.7	99
10	The UK EndoVascular Aneurysm Repair (EVAR) randomised controlled trials: long-term follow-up and cost-effectiveness analysis. Health Technology Assessment, 2018, 22, 1-132.	1.3	89
11	Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment, 2011, 15, i-xxi, 1-329.	1.3	84
12	Long-term cost-effectiveness analysis of endovascular <i>versus</i> open repair for abdominal aortic aneurysm based on four randomized clinical trials. British Journal of Surgery, 2014, 101, 623-631.	0.1	73
13	Cost-effectiveness of traditional and endovenous treatments for varicose veins. British Journal of Surgery, 2010, 97, 1815-1823.	0.1	70
14	Efficiency, Equity, and Budgetary Policies. Medical Decision Making, 2007, 27, 128-137.	1.2	56
15	Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	55
16	Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. British Journal of Dermatology, 2017, 176, 594-603.	1.4	55
17	Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ: British Medical Journal, 2009, 339, b2576-b2576.	2.4	54
18	Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. Health Economics (United Kingdom), 2017, 26, 109-123.	0.8	52

#	ARTICLE	IF	CITATIONS
19	The hospital costs of care for stroke in nine European countries. <i>Health Economics (United Kingdom)</i> , 2008, 17, S21-S31.	0.8	46
20	Paraplegia prevention in aortic aneurysm repair by thoracoabdominal staging with a minimally invasive staged segmental artery coil embolisation (MIS ² ACE): trial protocol for a randomised controlled multicentre trial. <i>BMJ Open</i> , 2019, 9, e025488.	0.8	46
21	A general framework for classifying costing methods for economic evaluation of health care. <i>European Journal of Health Economics</i> , 2020, 21, 529-542.	1.4	44
22	Cost-effectiveness of laparoscopic fundoplication versus continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial. <i>British Journal of Surgery</i> , 2013, 100, 1205-1213.	0.1	41
23	Cost-Effectiveness of Current and Emerging Treatments of Varicose Veins. <i>Value in Health</i> , 2018, 21, 911-920.	0.1	36
24	The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. <i>European Journal of Cancer</i> , 2011, 47, 2517-2530.	1.3	35
25	Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response. <i>Medical Decision Making</i> , 2005, 25, 511-519.	1.2	32
26	Systematic Review of the Effect of Adherence to Statin Treatment on Critical Cardiovascular Events and Mortality in Primary Prevention. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 200-215.	1.0	32
27	Randomized trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: Cost-effectiveness analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2006, 22, 67-75.	0.2	29
28	Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions. <i>Journal of Health Economics</i> , 2010, 29, 170-181.	1.3	29
29	Golimumab for the Treatment of Psoriatic Arthritis. <i>Pharmacoeconomics</i> , 2012, 30, 257-270.	1.7	28
30	Costs and prices for inpatient care in England: Mirror twins or distant cousins?. <i>Health Care Management Science</i> , 2006, 9, 233-242.	1.5	27
31	Uncertainty and value of information when allocating resources within and between healthcare programmes. <i>European Journal of Operational Research</i> , 2008, 191, 530-539.	3.5	27
32	Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model. <i>Medical Decision Making</i> , 2005, 25, 493-510.	1.2	25
33	Economic Evaluation of Coronary Artery Bypass Grafting Surgery With and Without Cardiopulmonary Bypass: Cost-Effectiveness and Quality-Adjusted Life Years in a Randomized Controlled Trial. <i>Artificial Organs</i> , 2008, 32, 891-897.	1.0	25
34	Long-term Clinical and Cost-effectiveness of Early Endovenous Ablation in Venous Ulceration. <i>JAMA Surgery</i> , 2020, 155, 1113.	2.2	25
35	Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. <i>Rheumatology</i> , 2011, 50, iv39-iv47.	0.9	24
36	A Procedure for Deriving Formulas to Convert Transition Rates to Probabilities for Multistate Markov Models. <i>Medical Decision Making</i> , 2017, 37, 779-789.	1.2	23

#	ARTICLE	IF	CITATIONS
37	COST-EFFECTIVENESS OF RADIOFREQUENCY ABLATION VERSUS LASER FOR VARICOSE VEINS. International Journal of Technology Assessment in Health Care, 2015, 31, 289-296.	0.2	20
38	The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial. Value in Health, 2016, 19, 431-439.	0.1	20
39	Evaluation of new medicines in Spain and comparison with other European countries. Gaceta Sanitaria, 2020, 34, 133-140.	0.6	18
40	Early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration: the EVRA RCT. Health Technology Assessment, 2019, 23, 1-96.	1.3	18
41	Social determinants of health: an economic perspective. Health Economics (United Kingdom), 2009, 18, 495-502.	0.8	17
42	Costâ€“Utility Analysis of a Pharmacotherapy Followâ€“Up for Elderly Nursing Home Residents in Spain. Journal of the American Geriatrics Society, 2014, 62, 1272-1280.	1.3	17
43	Cost-effectiveness analysis of a randomized clinical trial of early <i>versus</i> deferred endovenous ablation of superficial venous reflux in patients with venous ulceration. British Journal of Surgery, 2019, 106, 555-562.	0.1	17
44	How innovation can be defined, evaluated and rewarded in health technology assessment. Health Economics Review, 2022, 12, 1.	0.8	16
45	Cost-effectiveness analysis of current varicose veins treatments. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 504-513.e7.	0.9	15
46	Cost-effectiveness of supported self-management for CFS/ME patients in primary care. BMC Family Practice, 2013, 14, 12.	2.9	14
47	The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework. Journal of Market Access & Health Policy, 2019, 7, 1583536.	0.8	13
48	Modelling the cost-effectiveness of carotid endarterectomy for asymptomatic stenosis5. British Journal of Surgery, 2012, 100, 231-239.	0.1	12
49	The Stance4Health Project: Evaluating a Smart Personalised Nutrition Service for Gut Microbiota Modulation in Normal- and Overweight Adults and Children with Obesity, Gluten-Related Disorders or Allergy/Intolerance to Cowâ€™s Milk. Foods, 2022, 11, 1480.	1.9	10
50	Costs of an early intervention versus a conservative strategy in acute coronary syndrome. International Journal of Cardiology, 2008, 127, 240-246.	0.8	9
51	Modelling Correlated Clinical Outcomes in Health Technology Appraisal. Value in Health, 2011, 14, 793-799.	0.1	8
52	Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature. European Journal of Health Economics, 2016, 17, 1041-1053.	1.4	8
53	Costâ€“effectiveness of treatments for superficial venous reflux in patients with chronic venous ulceration. BJS Open, 2018, 2, 203-212.	0.7	8
54	Beyond the costâ€“effectiveness acceptability curve: The appropriateness of rank probabilities for presenting the results of economic evaluation in multiple technology appraisal. Health Economics (United Kingdom), 2019, 28, 801-807.	0.8	8

#	ARTICLE	IF	CITATIONS
55	Meeting public health objectives and supporting the resumption of tourist activity through COVID-19: a triangular perspective. <i>Current Issues in Tourism</i> , 2023, 26, 1617-1634.	4.6	8
56	Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells. <i>Bone Marrow Transplantation</i> , 2019, 54, 1908-1919.	1.3	7
57	Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?. <i>Value in Health</i> , 2020, 23, 25-31.	0.1	7
58	A multicenter randomized controlled study to evaluate whether neuromuscular electrical stimulation improves the absolute walking distance in patients with intermittent claudication compared with best available treatment. <i>Journal of Vascular Surgery</i> , 2019, 69, 1567-1573.	0.6	6
59	Consumers' Preferences and Willingness to Pay for Personalised Nutrition. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 757-767.	1.0	6
60	Cost-effectiveness of a primary care-based exercise intervention in perimenopausal women. The FLAMENCO Project. <i>Gaceta Sanitaria</i> , 2019, 33, 529-535.	0.6	5
61	Cost-effectiveness analysis of a surveillance program to prevent hip dislocation in children with cerebral palsy. <i>Gaceta Sanitaria</i> , 2020, 34, 377-384.	0.6	5
62	Compression hosiery to avoid post-thrombotic syndrome (CHAPS) protocol for a randomised controlled trial (ISRCTN73041168). <i>BMJ Open</i> , 2021, 11, e044285.	0.8	4
63	Análisis de coste-efectividad de la prueba de citología cervicovaginal. <i>Progresos En Obstetricia Y Ginecología</i> , 2012, 55, 304-311.	0.0	3
64	Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 15.	0.6	3
65	Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database. <i>European Journal of Health Economics</i> , 2022, 23, 1563-1575.	1.4	3
66	Use of Multiparameter Evidence Synthesis to Assess the Appropriateness of Data and Structure in Decision Models. <i>Medical Decision Making</i> , 2013, 33, 715-730.	1.2	2
67	Intensive rehabilitation may be more cost effective than surgical stabilisation for chronic low back pain. <i>Australian Journal of Physiotherapy</i> , 2005, 51, 269.	0.9	1
68	Optimizing Surveillance and Re-intervention Strategy Following Elective Endovascular Repair of Abdominal Aortic Aneurysms. <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e589-e598.	2.1	1
69	Study protocol for a multicentre, randomised controlled trial to compare the use of the decellularised dermis allograft in addition to standard care versus standard care alone for the treatment of venous leg ulceration: DAVE trial. <i>BMJ Open</i> , 2021, 11, e041748.	0.8	1
70	Development of the European Healthcare and Social Cost Database (EU HCSCD) for use in economic evaluation of healthcare programs. <i>BMC Health Services Research</i> , 2022, 22, 405.	0.9	1
71	Invited Commentary. <i>Journal of Vascular Surgery</i> , 2012, 56, 910.	0.6	0
72	A comparison of the accuracy of liquid cytology versus conventional screening: a meta-analysis of split-sample studies. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2014, 177, 153-168.	0.6	0

#	ARTICLE	IF	CITATIONS
73	COMMENT ON "HETEROGENEITY IN ACTION: THE ROLE OF PASSIVE PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH". Health Economics (United Kingdom), 2014, 23, 374-375.	0.8	0
74	IP273 Cost-Effectiveness of Current and Emerging Treatments of Varicose Veins. Journal of Vascular Surgery, 2017, 65, 128S.	0.6	0
75	Nutrition Economics: Celebrating Cross-Disciplinary Collaboration. Value in Health, 2021, 24, 313-316.	0.1	0
76	Comparing methods for handling missing cost and quality of life data in the Early Endovenous Ablation in Venous Ulceration trial. Cost Effectiveness and Resource Allocation, 2022, 20, 18.	0.6	0